Scott S. Emerson, M.D., Ph.D.
Professor Emeritus of Biostatistics
Department of Biostatistics
University of Washington

Consultation

Scott collaborates or consults on a broad range of clinical trials and other biostatistical areas. His participation as member or chair of Data Monitoring Committees for more than 75 clinical trials aligns closely with his research interests in the design, monitoring, and analysis of sequential and adpative clinical trials. He has also served on governmental advisory committees reviewing the design of randomized clinical trials, as well as on FDA advisory committees reviewing clinical trial results.

Scott's biostatistical collaborations and consultations have covered a broad spectrum of diseases including

• Cancer treatment: Lung, breast, prostate, lymphoma, leukemia, colorectal, skin, pancreatic, renal, gastrointestinal stromal tumors, melanoma, biliary, thyroid, ovarian
• Cardiovascular disease: Cardiac arrest, myocardial infarction, heart failure, stroke
• Endocrine, metabolic, and reproductive disease: diabetes, obesity, menopause, female sterilization
• Renal disease: Chronic renal failure, hyperphosphatemia
• Liver disease: Primary biliary cirrhosis
• Substance abuse: opioid use disorder
• Rheumatology and immunology: Rheumatoid arthritis, giant cell arteritis, systemic sclerosis, ankylosing spondylitis, Crohn's disease, peanut allergy
• Neurologic disease: Traumatic brain injury, multiple sclerosis
• Pulmonary disease: Pulmonary hypertension, cystic fibrosis, lung transplant, ARDS
• Hematologic disease: Iatrogenic thrombocytopenia, neutropenia, surgical bleeding
• Infectious disease: HIV, Hepatitis C, Hepatitis B, Community acquired pneumonia, Gram negative sepsis
• Genetic disease: Cystic fibrosis, phenylketonuria, Duchenne's muscular dystrophy
• Disease screening and prevention: Lung cancer, skin cancer, colorectal cancer, ovarian cancer, breast cancer, meningitis, hepatitis

Scott has collaborated on randomized clinical trials directed toward efficacy / effectiveness, noninferiority, equivalence, biosimilarity, and/or safety. These RCT often involved multiple treatments, multiple doses, and/or multiple endpoints. Designs included parallel arms, cross-over, cluster randomization (including cross-over), fully factorial designs, and partial factorial designs. RCT were often monitored with formal sequential adaptive rules that allowed sample size re-estimation, dropping dose groups or treatments, adaptive enrichment, and/or early termination for efficacy, futility, and/or safety.

Many of the novel methods used in the above trials have been described in technical reports and tutorials on the